Given the significant increase of CD23 mRNA levels including the individual variants in polyp tissues, significant associations with patient's clinical parameters such as atopy and asthma, and the positive correlations between IL5–CD23/CD23b, IL13–CD23, CD23a–PAX5, and AID–CD23/CD23a it might therefore be of interest to further investigate whether CD23 might serve as drug target for the local treatment of polyposis. The gene discussed is FCER2; the disease is polyposis.